Intarcia Therapeutics, Inc. presented final results from its Phase 1b clinical study of ITCA 650 (DUROS® continuous delivery of exenatide) for the treatment of type 2 diabetes, which demonstrate substantial reductions in fasting plasma glucose (FPG) within 24 hours of the start of treatment and a sustained glucose lowering effect throughout the 28 day treatment period.  Other important results from the study were significant reductions in postprandial glucose (PPG), HbA1c and body weight.

Read the release.

Advertisements